ACADIA Pharmaceuticals Q1 2024 GAAP EPS $0.10 Misses $0.12 Estimate, Sales $205.831M Miss $208.292M Estimate
Portfolio Pulse from Benzinga Newsdesk
ACADIA Pharmaceuticals (ACAD) reported Q1 2024 GAAP EPS of $0.10, missing the $0.12 estimate, with sales of $205.831M also missing the $208.292M estimate. This represents a 73.75% increase in sales compared to the same period last year.
May 08, 2024 | 8:42 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ACADIA Pharmaceuticals reported lower-than-expected Q1 2024 earnings and sales, missing estimates with an EPS of $0.10 and sales of $205.831M.
Missing both EPS and sales estimates typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price. However, the significant increase in sales year-over-year may mitigate some negative impact.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100